Background-In contrast with the histamine2 (H2) blockers, proton pump inhibitors have not been shown to give rebound hypersecretion of acid. Taking into consideration the hyperplasia of the enterochromaffin-like (ECL) cell provoked by hypergastrinaemia secondary to profound acid inhibition and the central role of histamine from ECL cells in the regulation of acid secretion, the lack of any rebound acid hypersecretion after treatment with proton pump inhibitors has been questioned. Aims-To reassess the effect of treatment with omeprazole on post-treatment acid secretion. Methods and Patients-Basal and pentagastrin stimulated acid secretion were determined in nine patients with reflux oesophagitis before and 14 days after termination of a 90 day treatment period with the proton pump inhibitor omeprazole (40 mg daily). Basal gastrin values as well as meal stimulated gastrin release were determined before and during omeprazole treatment. Furthermore, biopsy samples from the oxyntic mucosa were taken before and at the end of the treatment period for chemical (histamine and chromogranin A (CgA)) evaluation of the ECL cell mass. Results-A substantial increase in meal stimulated gastrin release during omeprazole treatment resulted in an increased ECL cell mass. Furthermore, CgA in serum increased during omeprazole treatment suggesting that serum CgA may be used as a test to evaluate ECL cell hyperplasia. A significant increase in basal and a marked (50%) and significant increase in pentagastrin stimulated acid secretion were found after treatment with omeprazole. Conclusions-Increased acid secretion after a conventional treatment period with a proton pump inhibitor is probably due to ECL cell hyperplasia and may have negative consequences for acid related diseases.
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In humans, gastrin is the main physiological regulator of gastric acid secretion.1 In the rat, gastrin stimulates acid secretion by releasing histamine2 from the enterochromaffin-like (ECL) cell.3 Also in humans6 and other species the stimulation of acid secretion by gastrin is probably mediated by the stimulation of histamine release from the ECL cell. 7 Gastrin not only regulates the function but also the growth of the ECL cell,8 an effect probably mediated by the same receptor, as the functional and trophic effects show the same concentration dependence in rat2 9 and man.' '°" We have previously shown that in the isolated rat stomach maximal histamine stimulated acid secretion is higher than maximal gastrin stimulated acid secretion.'2 In vivo, the apparently similar maximal gastrin and histamine stimulated acid secretion may be due to the toxicity of histamine making it impossible to administer histamine in a dose giving maximal gastric acid secretion.'3 Moreover, we have shown that gastrin stimulated histamine release depends on the ECL cell density or mass.F urthermore, longterm hypergastrinaemia secondary to profound acid inhibition has been reported to induce an increased capacity to secrete acid in the rat. ' with the other six H pylori negative patients. Although plasma gastrin only increased marginally in most of the patients, the integrated two hour gastrin response to the test meal increased substantially in all subjects (Table I ). The increase in meal stimulated gastrin release after omeprazole treatment depended on the meal stimulated release before treatment and increased threefold to fourfold compared with that before the treatment period (Table I) . Moreover, integrated meal stimulated gastrin release before (p=00357) as well as during (p=00238) omeprazole treatment was significantly increased in patients with H pylori infection.
Plasma histamine and CgA in serum Plasma histamine did not increase significantly during the omeprazole treatment period (Table I) . On the other hand, serum CgA increased in eight of the patients and was unchanged in the ninth (p=0.002) ( Table I) .
Gastric acid secretion Basal acid secretion increased significantly after omeprazole treatment (p<005). In one of the subjects, it became as high as 16 mmol/h (Figure) . Pentagastrin stimulated acid secretion increased in seven and was unchanged in one of the eight subjects studied (Figure) (p=0.004) . In one patient (patient 3) the acid secretion could not be assessed owing to heavy duodenogastric reflux (dark brown bilirubin stained gastric juice) on both occasions. Pentagastrin stimulated acid secretion was nearly doubled in patients 5 and 6, and a substantial increase was noted in all but two patients (patients 2 and 8).
Median pentagastrin stimulated acid secretion increased 50% (from 27.9 to 42-4 mmol/h). Histamine and CgA in the oxyntic mucosa Histamine increased significantly (p=002) in the oxyntic mucosa over the omeprazole treatment period (Table II) . The increase in CgA was even more marked and highly significant (p=0.004) (Table II) .
Discussion
For the first time a marked gastric acid hypersecretion after treatment with a proton pump inhibitor has been found in humans. This is in agreement with a previous study in rats where gastric acid hypersecretion was recorded one week after the end of longterm treatment with omeprazole.'5 24 The acid hypersecretion in these rats persisted for at least 70 days. '5 24 Previously, tolerance to H2 blockers has been described whereas no such tolerance has been reported after treatment with proton pump inhibitors.25 Rebound In the present study basal gastric juice in patient 3 was not only bile stained, but also alkaline. Therefore, it was quite clear that the secretory data from this patient could not be used in the assessment of rebound acid hypersecretion in this study. Ideally, this patient should have been removed from the study at the initial phase because of the observed duodenogastric reflux. However, exclusion of this patient would have meant that only two patients with Hpylori infection would have had pre-and post-treatment acid secretion determined. In one of these patients (patient 8) both basal and pentagastrin stimulated acid secretion were unaffected by the treatment with omeprazole whereas it increased markedly in the other patient (patient 6) with H pylori infection (pentagastrin stimulated acid secretion increased from 27.3 to 47-8 gmol/h).
The effect of omeprazole persists for at least one week.27 Therefore, it is mandatory to wait for longer than this to be able to detect rebound acid hypersecretion. In the present study we determined acid secretion two weeks after the end of treatment with the proton pump inhibitor and detected an increased pentagastrin stimulated as well as basal acid secretion. In vivo 24 hour gastric acidity reflects basal as well as food stimulated acid secretion. Since gastrin is the dominating secretagogue for meal stimulated acid secretion,1 the described increase in pentagastrin stimulated acid secretion would be expected to lead to an augmented food stimulated acid secretion. Furthermore, as longterm inhibition of acid secretion also leads to an increase in antral G cells and decrease in somatostatin (D) cells,30 food stimulated acid secretion after long-term treatment with potent inhibitors of acid secretion could lead to an even more marked acid hypersecretion than detected by pentagastrin stimulated acid secretion. It is possible that GRP stimulated acid secretion33 could be an even more sensitive test for post-treatment acid hypersecretion. The clinical impact of this post-treatment acid hypersecretion remains to be shown. However, gastric acid plays a pathogenetic part in both peptic ulcer disease and reflux oesophagitis. Therefore, it is conceivable that.the demonstrated acid hypersecretion may have a negative effect and contribute to the recurrence of both these diseases. The hypergastrinaemia secondary to the inhibition of acid secretion by omeprazole probably induced the post-treatment gastric acid hypersecretion. Basal gastrin increased in all subjects during treatment. The increase in basal gastrin was, however, slight or moderate with a value above 100 pmol/l in only one patient. However, even moderate hypergastrinaemia has a significant trophic effect on the ECL cell.9
Furthermore, as shown in this study, basal gastrin values during treatment with proton pump inhibitors underestimate the postprandial hypergastrinaemia, which was greatly increased in all subjects during omeprazole treatment. Thus, the 24 hour gastrin stimulation is considerably raised in patients treated with proton pump inhibitors. Taking into consideration that the maximal trophic effect of gastrin on the ECL cell is reached at a lower concentration than previously thought in humans,'0 as in the rat,9 it is probable that near maximal stimulation of ECL cell growth was obtained during a greater part of the day in some of the patients, for instance patients 3 and 6, who both had postprandial gastrin values just above 170 pmolll (Table I) .
It is now established that the ECL cell plays a central part in the regulation of gastric acid secretion.7 Furthermore, it is probable that gastrin induced histamine release is the limiting factor for gastric acid secretion after gastrin stimulation as well as meal stimulated acid secretion. 34 We found an increased histamine concentration in the oxyntic mucosa after omeprazole treatment, which probably reflects an increase in the ECL cell mass, especially as it was accompanied by a similar increase in CgA. An increased ECL cell density in the oxyntic mucosa in humans is well known after omeprazole treatment. 16 Lamberts et al reported a doubling of the density of argyrophil cells in the oxyntic mucosa in patients with peptic ulcer treated with omeprazole for one to two years at the dose of 40 mg daily.'6 Taking into consideration that the ECL cell, the only argyrophilic cell in the oxyntic mucosa where gastrin has a positive trophic effect,35 normally represents only 35% of these cells,36 a doubling of the density of the argyrophilic cells probably indicates an even more marked increase in the ECL cell density than just a doubling. Furthermore, gastrin has a negative trophic effect on the D cell in the oxyntic mucosa.37 Accordingly, the described increase in argyrophilic cell density represents a massive increase in the ECL cell mass and function in the oxyntic mucosa. On the other hand, proton pump inhibitor treatment seems not to induce an increase in parietal cell density. '5 Longterm hypergastrinaemia in humans is accompanied by gastric acid hypersecretion.38 This gastric acid hypersecretion may be controlled by treatment with proton pump inhibitors in normal doses,39 whereas H2 blockers have to be used in greatly increased doses,40
suggesting an increase in the histamine concentration in the oxyntic mucosa. 34 Altogether, the findings of this study and previous studies'6 [34] [35] [36] [37] [38] [39] [40] suggest that increased histamine due to ECL cell hyperplasia is the most important mechanism for increased acid secretory capacity after prolonged hypergastrinaemia. Furthermore, this study shows that CgA in blood may be used to assess the neuroendocrine cell mass in the stomach whereas plasma histamine cannot be used to estimate the ECL cell mass (Table I) . Contamination of histamine released from granulocytes at the blood sampling and preparation of plasma'o is probably the main reason for the lack of correlation between plasma histamine on one hand and serum CgA or ECL cell mass on the other.
In conclusion, this study shows for the first time that treatment with a proton pump inhibitor in a conventional dose even in humans induces post-treatment gastric acid hypersecretion, which may have negative influences on the diseases for which they were prescribed. Furthermore, this increase in acid secretion is probably due to an increased ECL cell mass secondary to hypergastrinaemia during the treatment period.
capacity after omeprazole treatment. 
